NeuroSense Therapeutics (NRSN) announced promising new findings from its Phase 2b PARADIGM clinical trial. The data highlights the significant impact of PrimeC, the company’s investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS), on microRNA (miRNA) modulation.
These data are particularly significant because they represent an important development in understanding how the therapy may slow disease progression in people living with ALS. They reveal the consistent effect of PrimeC on altering the expression of miRNAs associated with ALS, reinforcing its potential role in addressing key pathological processes in ALS, while aligning with the previously reported clinical benefits, including the 33% reduction in disease progression and 58% improvement in survival rates observed with PrimeC treatment.
